<DOC>
	<DOC>NCT00830869</DOC>
	<brief_summary>This is an open-label, multicenter, phase 1, dose escalation study of IXAZOMIB. The primary purpose of this study is to determine the safety profile, establish the maximum tolerated dose, and inform the phase 2 dose of IXAZOMIB administered intravenously in patients with nonhematologic malignancies.</brief_summary>
	<brief_title>A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>Each patient must meet all of the following inclusion criteria to be enrolled in the study: 1. Male or female patients 18 years or older 2. Eastern Cooperative Oncology Group performance status 02 3. A diagnosis of a nonhematologic malignancy for which standard treatment is no longer effective. In the expanded cohort, enrollment will be limited to patients with a diagnosis of NSCLC, head and neck cancer (squamous cell cancer), soft tissue sarcoma, or prostate cancer 4. Suitable venous access PK and pharmacodynamic evaluations 5. Female patients who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or abstain from heterosexual intercourse Male patients who agree to to practice 2 effective methods of contraception or abstain from heterosexual intercourse. 6. Voluntary written consent must be obtained 7. Adequate clinical laboratory values during the screening period Patients meeting any of the following exclusion criteria are not to be enrolled in the study: 1. Peripheral neuropathy â‰¥Grade 2 2. Female patients who are lactating or have a positive serum pregnancy test during the screening period 3. Major surgery within 14 days before the first dose of treatment 4. Infection requiring systemic antibiotic therapy or other serious infection within 14 days before the first dose of study treatment 5. Lifethreatening illness unrelated to cancer 6. Diarrhea &gt;Grade 1 based on the NCI CTCAE categorization 7. Systemic antineoplastic therapy / or radiotherapy within 21 days before the first dose of study treatment 8. Systemic treatment with prohibited medications 9. Patient has symptomatic brain metastasis 10. Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure (CHF), angina, or myocardial infarction within the past 6 months 11. QTc &gt;470 milliseconds (msec) on a 12lead electrocardiogram (ECG) obtained during the screening period 12. Known human immunodeficiency virus (HIV), hepatitis B and hepatitis C positive 13. Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol 14. Treatment with any investigational products within 28 days before the first dose of study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>